A b s t r a c t
Primary liver cancer is the fifth most common malignancy worldwide, and the incidence of this cancer type is increasing. It is also the third leading cause of cancerrelated death; only cancers of the lung and stomach result in more deaths worldwide. 1 Hepatocellular carcinoma (HCC) accounts for 85% to 90% of primary liver cancers. 2 It develops mostly in cirrhotic livers, and the risk factors include chronic infection by hepatitis B and C viruses and nonviral liver diseases. 3 The prognosis of HCC has improved because of significant enhancements in surgical techniques and diagnostic methods in recent years. However, the long-term prognosis is still unsatisfactory due, primarily, to the high recurrence and invasion rates even after resection (50%-70% at 5 years). 4, 5 Unfortunately, little is known about the cellular mechanisms underlying hepatocarcinogenesis. Thus, the development of a reliable prognostic biomarker to allow clinicians to predict the characteristics of the malignancy and, therefore, to decrease the rate of unfavorable outcomes in members of high-risk populations is of great interest.
Ras and Rab interactor 1 (RIN1), located at chromosome 11q13.2, was first isolated as an RAS effector that directly interacts with active Ras. 6 A subsequent analysis of full-length RIN1 clones showed that the protein product of this gene binds with high affinity and high specificity to activated HRAS. 6 Recent studies have demonstrated that RIN1 plays an important role in mediating signal transduction. In addition to active Ras proteins, several interaction partners have been identified, including Rab5, 7 ABL tyrosine kinases, 8 signal-transducing adapter molecule, 9 epidermal growth factor receptor (EGFR), 10 and 14-3-3 proteins. 11 Two downstream RIN1 effector pathways have been described. The first pathway involves direct activation of RAB5-mediated endocytosis. 12 The second pathway involves direct activation of ABL tyrosine kinase activity. 13 Recent studies have indicated a potential role for altered RIN1 expression and function in tumor development and progression. In breast cancer, RIN1 expression is reduced or silenced in tumor tissues and cell lines compared with adjacent normal breast tissues and normal breast glandular cells. 12 However, RIN1 expression is increased in gastric adenocarcinoma, 14 colorectal cancer, 15 non-small cell lung cancer, 16 and bladder urothelial carcinoma. 17 Studies have shown that RIN1 plays an important role in human tumor progression and development. Furthermore, to our knowledge, no reports describing the expression of RIN1 in HCC have been published. In this article, we explore the relationship between RIN1 expression, its clinical features, and overall survival (OS) after resection. We also explore the effect of cell migration and invasion by transfecting HCC cells with pEGFP-N1-RIN1.
Materials and Methods

Patient Tissue Samples
A total of 102 HCC specimens were collected from patients who had undergone routine hepatic resection at the First Affiliated Hospital of China Medical University, Shenyang. None of the patients had been pretreated with preoperative radiotherapy or chemotherapy prior to the surgical resection. Patients were followed up until December 2009. Enhanced computed tomography scan or B ultrasound was applied for rechecking patients. Histologic diagnosis and differentiation were evaluated independently by 2 pathologists according to the World Health Organization classification system. 18 The clinicopathologic features are shown in ❚Table 1❚. In addition, 25 paired fresh specimens, including both tumor tissues and the corresponding paired noncancerous parenchyma, were snap-frozen in liquid nitrogen and stored at -70°C immediately after resection until processing. Prior to the initiation of this study, the project protocol was approved by the Institutional Ethics Committee of the China Medical University. All patients provided written informed consent for the use of the tumor tissues for clinical research.
Immunohistochemistry
The expression of RIN1 was analyzed by immunohistochemistry (IHC) on 5-mm-thick tissue sections fixed with 10% formalin and embedded in paraffin. The following antibody was used: goat anti-RIN1 (1:200; Santa Cruz Biotechnology, Santa Cruz, CA). Sections were stained with 3,3'-diaminobenzidine. Normal rabbit serum was used as a negative control.
The immunoreaction was subjectively assessed by 2 experienced pathologists under double-blind conditions. The pathologists had no prior knowledge of the clinical or clinicopathologic status of the specimens. RIN1-expressing cells were scored semiquantitatively according to the number of positive-staining cells and the staining intensity. Nuclear and/or cytoplasmic immunostaining in the tumor cells was considered positive staining. The percentage of positive cells was defined as 0 (0%), 1 (1%-10%), 2 (11%-50%), 3 (51%-80%), or 4 (>80%). The intensity of staining was classified as 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (strong staining). The final score (ranging from 0-12) was calculated from the value of the percent positive score multiplied by the staining intensity score. RIN1 expression in tumors was divided into the following categories: negative (-), score 0; low expression (1+), score 1 to 4; moderate expression (2+), score 4 to 8; and strong expression (3+), score 9 to 12. The immunohistochemical results of RIN1 were grouped into 2 categories: low expression (0 to 1+) and high expression (2+ to 3+). 
RNA Isolation and Real-Time Polymerase Chain Reaction
The total RNA was isolated from the frozen tumor specimens with a TRIzol reagent (Takara, Otsu, Japan) according to the manufacturer's instructions. Reverse transcription was performed using 0.5 mg total RNA from each sample. Realtime quantitative polymerase chain reaction (RT-qPCR) was performed using the SYBR Green PCR Master Mix (Takara). The sequences of the primer pairs were as follows: RIN1 (forward), 5'-GGCAGCAGAGGAGTAGCTTGA-3'; RIN1 (reverse), 5'-GCTTGCTGGCGCTAAAAGG-3'; GAPDH (forward), 5'-ATAGCACAGCCTGGATAGCAACGTAC-3'; and GAPDH (reverse), 5'-CACCTTCTACAATGAGCTGC-GTGTG-3'. The experiments were repeated in triplicate. The relative levels of gene expression were represented as ΔCt = Ct of RIN1 -Ct of GAPDH, and the fold change of gene expression was computed using the 2 -ΔΔCt method.
Western Blot
The total protein from the tissues and cells was extracted in lysis buffer (Beyotime, Shanghai, China) and quantified using the Bradford method. An 80-mL aliquot of total protein was subjected to sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis and then electrotransferred to a PVDF membrane (Millipore, Billerica, MA). The membranes were blocked with 5% skim milk at room temperature for 2 hours. After blocking, the primary antibodies, including RIN1 goat polyclonal antibody (1:1,000; Santa Cruz Biotechnology), mouse anti-ABL2 (1:1,000; Abcam, Cambridge, MA), mouse anti-matrix metalloproteinase 9 (MMP-9) (1:500; Santa Cruz Biotechnology), rabbit anti-E-cadherin (1:1,000; Abcam), and mouse anti-β-actin (1:500; Santa Cruz Biotechnology), were incubated on the PVDF membranes at 4°C overnight. Then, the membranes were incubated for 2 hours at room temperature with secondary antibodies (1:5,000; Beyotime). The protein bands were identified using an ECL system (Pierce, Rockford, IL) according to the manufacturer's protocol.
Cell Culture and Transfection
The human HCC HepG2 cell line was obtained from the Cell Biology China Academy of Science (Shanghai, China) and maintained as recommended. The cells were cultured in Dulbecco modified Eagle medium (DMEM) (high glucose; Invitrogen, Carlsbad, CA) containing 10% fetal calf serum and incubated in a humidified atmosphere of 5% CO 2 at 37°C. The eukaryotic expression vector pEGFP-N1-RIN1 was purchased from GeneChem (Shanghai, China). The human HCC cell line HepG2 was plated at a density of 1 × 10 4 cells per well in 24-well culture plates. The cells were cultured overnight and then transfected with the expression vector pEGFP-N1-RIN1 or pEGFP-N1 using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's recommendation. RIN1 expression was confirmed by a Western blot analysis.
Transwell Assay
The cells (2 × 10 5 ) were mixed with 200 mL serum-free DMEM and dropped onto the upper layer of the chamber, which was coated with 20 mL Matrigel (1:4 dilution; Costar, Corning, NY). The lower layer was supplemented with DMEM containing 10% fetal bovine serum. After 48 hours of incubation at 37°C, the cells that penetrated the membrane were fixed with 4% paraformaldehyde for 30 minutes at room temperature and stained with 0.1% crystal violet for 15 minutes. The upper surface of the chamber was wiped with a cotton-tipped swab. The invading cells were counted in 5 fields of view at ×200. The experiments were carried out in triplicate.
Statistical Analysis
All statistical analyses were performed using SPSS 17.0 for Windows (SPSS, Chicago, IL). The association between RIN1 expression and HCC patient clinicopathologic features was evaluated using the χ 2 test. The Wilcoxon signed rank test or t test was performed to compare the data obtained from the densitometry analysis of the messenger RNA (mRNA) and protein expression. The Kaplan-Meier method was used to calculate the patient OS, and the data were compared using a log-rank test. A Cox regression model was used to determine the univariate and multivariate analysis prognostic variables. All P values quoted were 2-sided, and P values less than .05 were considered statistically significant.
Results
RIN1 Expression in HCC
The expression level of RIN1 in 25 pairs of primary HCC and their corresponding noncancerous liver tissues was examined with RT-qPCR and normalized against an endogenous control (GAPDH). We found that the median RIN1 mRNA expression in primary HCCs was lower than that of the noncancerous counterparts (median expression = 0.216 and 0.427, respectively), and overall RIN1 was significantly downregulated in primary HCC samples (P < .05, Wilcoxon signed rank test) ❚Figure 1❚. When comparing paired primary HCCs with their corresponding nontumorous livers, downregulation of RIN1 was observed in 19 (76%) cases. At the protein level, we analyzed 4 representative tissues (tumor samples and adjacent normal tissue from the same patient) using IHC and Western blot. As shown in ❚Image 1❚ and ❚Image 2❚, the RIN1 protein level trend is consistent with the RT-qPCR results. In short, RIN1 expression was lower in the cancer lesions than in the areas adjacent to the tumor.
Clinical Significance of RIN1 Expression in HCC
Our study further showed that RIN1 was expressed at lower levels in 72 tumor samples (mean ± SD score, He_2012110606.indd 76 6/5/13 11:58 AM 2.17 ± 1.34; 102 cases total). The RIN1 protein seemed to be located in the nuclear membrane/nucleus and the cytoplasm of the tumor cells ❚Image 3❚. However, the surrounding normal tissues appeared to strongly express RIN1 (mean ± SD score, 7.43 ± 2.11, P < .05; Image 1). As indicated by the clinicopathologic factors in Table 1 , some patients with low RIN1 expression had invasion (Table 1 ; P = .01), but others did not (P > .05). The OS was higher in patients with HCC with high RIN1 expression than in those with HCC with low RIN1 expression (P < .001) ❚Figure 2❚. In addition, a multivariate analysis using the Cox model indicated that RIN1 was an independent, favorable prognostic factor (hazard ratio, 0.475; P = .007), but invasion was an unfavorable prognostic factor (hazard ratio, 2.325; P = .002) ❚Table 2❚.
C C D D C, Case 13 (×400). D, Case 21 (×400).
❚Image 2❚ RIN1 protein expression in each of the hepatocellular carcinoma samples (T) and the normal tissues (N) that were paired from the patient samples and that had been previously analyzed by a Western blot analysis.
Overexpression of RIN1 Suppresses Tumor Cell Invasion in HCC Cell Lines
To explore the mechanism by which RIN1 inhibits the invasive ability of HepG2 cells, we examined the protein was depleted. This depletion led to a reduction in EGFR signaling. A recent study 12 showed that RIN1 acted as a suppressor gene in breast tumors. The RIN1 promoter contains 20 binding sites for SNAI1, which is a transcriptional inhibitor of epithelial genes, such as E-cadherin. This study showed that SNAI1 can repress the expression of RIN1. A study of breast cancer cell lines showed that the ZR75-1 cell line had 4 times higher SNAI1 expression than did the MCF10A cell line. Conversely, when RIN1 expression was restored, RIN1 functioned via ABL tyrosine kinases to block invasion. One reason for these different mechanisms is that the localization of RIN1 varies between cancer types. Another explanation is that the cells used in these studies were of different types and origins. In our study, the IHC results showed that RIN1 was located in the nuclear membrane/nucleus and cytoplasm. Therefore, RIN1 may play a role in the cell membrane signaling pathway. The RIN1 protein has 4 functional domains. One of these functional domains is the ABL binding domain levels of RIN1, ABL2, MMP-9, and E-cadherin in the HepG2 cell line. ❚Image 4❚ shows that the expression of RIN1 is positively correlated with the expression of ABL2. The same positive correlation was observed between RIN1 and E-cadherin. However, RIN1 expression is negatively correlated with MMP-9 expression ❚Image 5❚. As shown in ❚Image 6❚, RIN1 overexpression blocked HepG2 cell invasion, as measured by a Transwell assay. The mean ± SD number of invading cells was 55.7 ± 8.92 in the pEGFP-N1-RIN1 group (RIN1), 125.6 ± 15.43 in the pEGFP-N1 (used as a negative control) group, and 117 ± 9.46 in the HepG2 cell line (HepG2) group.
Discussion
The RIN1 gene exhibits variable expression levels in various tumors. However, the subcellular localization and expression of RIN1, as well as its correlation with clinicopathologic factors in HCC, have not yet been identified. In our study, we demonstrated that RIN1 expression in HCC samples was significantly lower than that of the noncancerous counterpart tissues at both the RNA and protein levels. RIN1 expression in the HCC samples closely correlated with invasion. Moreover, RIN1 overexpression correlated with a good prognosis in patients with HCC. In addition, we revealed that both overexpression and downregulation of RIN1 in a liver cancer cell line altered the invasive potential of the cells.
RIN1 was discovered as an RAS effector, and its interaction with RAS was characterized in yeast and human models in the 1990s. 19, 20 For nearly 2 decades, the functional mechanism of RIN1 within various tumors has been studied. Previous studies showed that RIN1 inhibited mammary epithelial cell migration and invasive growth. 8, 10, 21 Likewise, stable transfection of RIN1 in MDA-MB-231 cells had a lower capacity for invasion compared with the vector control. 12 In this study, we observed similar results. Specifically, the clinical data analysis showed a correlation between low expression levels of RIN1 and invasion in patients with HCC. The results of Transwell cell migration tests using coated chambers also suggested that RIN1 overexpression abolished HepG2 cancer cell invasion. Our data showed that RIN1 is involved in the regulation of cell migration.
RIN1 has different mechanisms of action in different tumor types. In colorectal cancer, 15 RIN1 is expressed only in the cytoplasm and not at the cell membrane. This localization results in a failure of RIN1 to fulfill its original function (to inhibit the cell growth mediated by competition with Ras and RAF1). In a non-small cell lung cancer cell line, the cell proliferative ability was reduced when RIN1 ❚Image 4❚ RIN1 and ABL2 protein expression evaluation after transfection with pEGFP-N1-RIN1 (RIN1), pEGFPN1 (NC), or blank control (HepG2) for 48 hours in HepG2 cell lines using Western blot.
❚Image 5❚ E-cadherin and matrix metalloproteinase 9 (MMP-9) protein expression after transfection with pEGFP-N1-RIN1 (RIN1), pEGFP-N1 (NC), or blank control (HepG2) for 48 hours in HepG2 cell lines using Western blot.
Matrix metalloproteinases are widely known to play an important part in the degradation of the extracellular matrix (ECM) and cause cell progression. MMP-9 has been demonstrated to promote tumorigenesis in different tumor cells and relates to invasion and poor prognosis in different kinds of tumors. [26] [27] [28] By influencing ECM, MMPs can induce the occurrence of EMTs, 29 so is it possible that RIN1 expression affects HCC progression through its effect on MMPs and E-cadherin? Image 5 demonstrates the expression of E-cadherin and MMP-9 before and after plasmid transfection in HepG2 cancer cells. We observed obvious changes in the expression levels of these molecules. It could be argued that RIN1 may function as a tumor suppressor gene to affect carcinogenesis by possibly regulating MMP-9 and E-cadherin in liver cancer cells.
Hu et al 8 discovered that the ABD of RIN1 can increase the expression of ABL2-mediated p-CRK and inhibit EMTs.
(ABD, aa1-295). 6 Both ABL1 and ABL2 have similar structures (such as SH2, SH3, and TK domains) and functions. 22 Previous studies presented evidence that RIN1 functioned in various ways to maintain epithelial integrity. By activating ABL tyrosine kinases, RIN1 could block tumor invasiveness. 12 This result is consistent with another study that showed that ABL played a negative role in cancer cell tumorigenicity. 23 Image 4 shows that the expression levels of RIN1 and ABL2 were positively correlated before and after RIN1 plasmid transfection. We considered that ABL2, possibly associated with RIN1, may take part in HCC tumorigenesis.
E-cadherin is widely expressed in normal epithelial cells, which is significant to maintain cell-cell adhesion. It has been reported to inhibit tumor metastasis, 24, 25 and its expression level is negatively correlated with the occurrence of epithelial-to-mesenchymal transitions (EMTs).
A B C ❚Image 6❚ Overexpression of RIN1 in HepG2 cell lines by pEGFP-N1-RIN1 transfection inhibits cell invasion. A, Blank control (HepG2) (×200). B, pEGFPN1 (NC) (×200). C, pEGFP-N1-RIN1 (RIN1) (×200).
